Method for separating and detecting genotoxic impurities in brexpiprazole and application thereof
Through the optimization of high-performance liquid chromatography and combined with the ghost peak capture column, the problem of insufficient detection sensitivity of genotoxic impurities in brapiprazole is solved, efficient separation and detection is achieved, and drug quality and drug safety are ensured.
Patent Information
- Application Number
- CN202310508285.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-08
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art has insufficient sensitivity when detecting genotoxic impurities in brapiprazole, which is difficult to meet the high requirements of genotoxic impurities, affecting the quality of drugs and the safety of medication.
High performance liquid chromatography was used, and C18 column was used, mobile phase A was used as aqueous phosphate solution, mobile phase B was acetonitrile, gradient elution was combined with ghost peak capture column, and chromatographic conditions were optimized to improve detection sensitivity and efficiency.
It realizes efficient separation and detection of genotoxic impurities in brapiprazole, improves detection sensitivity and efficiency, ensures drug quality and drug safety, is simple and easy to use, and is suitable for industrial production.
Smart Images

Figure BDA0004216353560000011 
Figure BDA0004216353560000031 
Figure BDA0004216353560000111
Abstract
Description
Technical Field
[0001] The invention relates to the field of drug analysis, and in particular to a method for separating and detecting genotoxic impurities in breprazole and an application thereof. Background Art
[0002] Brexiprazole, also known as brexpiprazole (trade name Rexulti), is a partial agonist of serotonin receptor 5-HT1A and dopamine receptors D2 and D3, and a partial antagonist of serotonin receptors 5-HT2A and 5-HT2B, as well as adrenergic receptors α-1 and α-2. It is used to treat schizophrenia and as an adjunctive treatment for major depressive disorder.
[0003]
[0004] Genotoxic impurities refer to impurities that can cause genotoxicity, including mutagenic impurities and other types of non-mutagenic impurities. They mainly come from the production process of raw materials, such as starting materials, reactants, catalysts, reagents, solvents, intermediates, by-products, degradation products, etc. Potential genotoxic impurities refer to impurities that contain chemical structures similar to the reactivity of genotoxic impurities, namely structural alerts (SAs), which are usually also evaluated as genotoxic impurities. Genotoxic impurities and potential genotoxic impurities may be brought into the final product, affecting product quality and increasing the risk of drug users. Therefore, the development of scientific and reasonable separation and detection methods is of great significance to ensure the quality of drugs, ensure the safety and effectiveness of drugs, and then achieve controllable drug quality.
[0005] CN109307716A discloses a method for detecting related substances of epiridol by high performance liquid chromatography. The liquid chromatography determination conditions are as follows: the chromatographic column is filled with octadecylsilane bonded silica gel, the mobile phase A is acetonitrile, the mobile phase B is phosphate buffer-acetonitrile, and the elution is gradient.
[0006] In the process of genotoxicity control, an important concept is the threshold of toxicological concern (TTC), whose limit (1.5 μg / d) is used as the acceptable limit of genotoxic impurities. The limit of genotoxic impurities calculated based on this limit is usually at the ppm level, which puts higher requirements on the sensitivity of the analytical method.
[0007] In view of this, the present invention provides a method for separating and detecting genotoxic impurities in brepirazolide, which can improve detection sensitivity and detection efficiency, facilitate quality control of brepirazolide, and further improve clinical drug safety. Summary of the invention
[0008] One of the purposes of the present invention is to provide a method for separating and detecting genotoxic impurities in brepazole by high performance liquid chromatography, wherein the chromatographic column is a C18 column, the mobile phase A is a phosphate aqueous solution, the mobile phase B is acetonitrile, and the gradient elution is performed, and the related substance is selected from any one of impurity A, impurity B, impurity C, and impurity D or a combination thereof.
[0009] In the preferred technical solution of the present invention, the structure of the related substance is as follows:
[0010]
[0011]
[0012] In a preferred technical solution of the present invention, the phosphate is selected from any one of potassium dihydrogen phosphate, sodium dihydrogen phosphate, dipotassium hydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, potassium phosphate, or a combination thereof.
[0013] In a preferred technical solution of the present invention, the concentration of the phosphate aqueous solution in the mobile phase A is 5 to 20 mmol / L, preferably 8 to 15 mmol / L.
[0014] In a preferred technical solution of the present invention, an acid is added to the mobile phase A, and the acid is selected from any one of phosphoric acid, formic acid, and acetic acid, or a combination thereof.
[0015] In the preferred technical solution of the present invention, the pH value of mobile phase A is 2.2 to 3.0, preferably 2.2 to 2.5.
[0016] In the preferred technical solution of the present invention, the specification of the chromatographic column is any one of 50*2.1mm, 100*2.1mm, 100*4.6mm, 150*3mm, 150*4.6mm, 250*3mm, and 250*4.6mm.
[0017] In a preferred technical solution of the present invention, the particle size of the chromatographic column filler is any one of 1.7 μm, 1.8 μm, 3 μm or 5 μm.
[0018] In the preferred technical solution of the present invention, a ghost peak capture column is installed between the pump and the injector of the high performance liquid chromatograph.
[0019] In the preferred technical solution of the present invention, the ghost peak capture column has a specification of 4.6×50 mm.
[0020] In the preferred technical solution of the present invention, the flow rate of the mobile phase is 0.5 to 2 ml / min, preferably 0.8 to 1.5 ml / min.
[0021] In a preferred technical solution of the present invention, the injection volume is 5 to 50 μl, preferably 10 to 20 μl.
[0022] In the preferred technical solution of the present invention, the column temperature is 25-45°C, preferably 35-45°C.
[0023] In the preferred technical solution of the present invention, the detection wavelength is 220-240 nm, and the preferred detection wavelength is selected from any one of 220 nm, 230 nm, and 240 nm.
[0024] In the preferred technical solution of the present invention, at 0 to 50 minutes, the volume ratio of mobile phase A:mobile phase B is 90:10 to 30:70.
[0025] In the preferred technical solution of the present invention, after 50 minutes, the volume ratio of mobile phase A:mobile phase B is 80:20-90:10, which is maintained for 5 to 20 minutes.
[0026] In the preferred technical solution of the present invention, the elution procedure of the gradient elution is:
[0027] Time (min) Mobile phase A (%) Mobile phase B (%) 0 85 15 50 30 70 50.1-60 85 15
[0028] In a preferred technical solution of the present invention, any one of the test substance, the test sample, and the reference substance is dissolved or diluted with a dissolving solvent, and the dissolving solvent is a combination of water, acetonitrile, methanol, and glacial acetic acid.
[0029] In the preferred technical solution of the present invention, the volume ratio of water, acetonitrile, methanol and glacial acetic acid in the dissolving solvent is 50:40:10:1.
[0030] In a preferred technical solution of the present invention, the separation degree between any of the substances to be detected in the detection method is not less than 1.5, preferably not less than 2.0.
[0031] In the preferred technical solution of the present invention, the contents of impurity A, impurity B, impurity C and impurity D in breprazol are not more than 375 ppm.
[0032] In the preferred technical solution of the present invention, the peaks in the high performance liquid chromatography should be in the order of impurity C, impurity A, impurity D, and impurity B.
[0033] Another object of the present invention is to provide the use of any one of brepirazole and / or its genotoxic impurities separated and purified by the separation and detection method of the present invention as a standard or reference substance.
[0034] In a preferred technical solution of the present invention, the genotoxic impurity is selected from any one of impurity A, impurity B, impurity C, impurity D or a combination thereof.
[0035] Another object of the present invention is to provide a method for separating and detecting brepizole and / or impurity A, impurity B, impurity C, and impurity D by high performance liquid chromatography, and the use of the method in the quality control of brepizole raw materials and / or their preparations.
[0036] In a preferred technical solution of the present invention, the brepizole preparation is selected from a brepizole solid preparation or a liquid preparation.
[0037] In a preferred technical solution of the present invention, the brepazole solid preparation is selected from any one of tablets, capsules, powders, granules, dry suspensions, and pellets.
[0038] In a preferred technical solution of the present invention, the brepazole liquid preparation is selected from any one of an oral solution, a syrup, an injection, a spray, and a suspension.
[0039] Unless otherwise specified, the equivalents described in the present invention are all based on weight.
[0040] Unless otherwise specified, when the present invention relates to the percentage between liquids, the percentage is volume / volume percentage; when the present invention relates to the percentage between liquids and solids, the percentage is volume / weight percentage; when the present invention relates to the percentage between solids and liquids, the percentage is weight / volume percentage; the rest are weight / weight percentages.
[0041] Compared with the prior art, the present invention has the following beneficial technical effects:
[0042] 1. The present invention achieves effective separation and detection of brepirazole and / or its genotoxic impurities, potential genotoxic impurities, and various related substances with similar structures and difficult to separate generated during the preparation and storage of brepirazole APIs and preparations by scientifically screening and optimizing the detection conditions of high performance liquid chromatography, including optimizing chromatographic conditions and gradient elution conditions. The separation degree between brepirazole and any related substance to be detected in the high performance liquid chromatography of the present invention is not less than 2.0, and can be used for separation, content determination, preparation and purification of brepirazole or its derivatives, related substances, or monitoring of its related substances.
[0043] 2. The high performance liquid chromatography method of the present invention has the advantages of good specificity and high sensitivity, and realizes the effective separation of brepirazole and its genotoxic impurities, and the detection limit of genotoxic impurities is extremely low. The method is conducive to the quality control of brepirazole, its raw materials and preparations, ensures the quality and safety of drugs, is simple and easy to operate, helps to reduce production and testing costs, and is suitable for the relevant requirements of industrial and large-scale production.
[0044] 3. The present invention is used to prepare and separate brepirazole and its genotoxic impurities, and use them as reference substances or standard substances for brepirazole and its derivatives, brepirazole APIs or their preparations, and to control the quality of APIs, intermediates or preparations, and to ensure the quality and safety of drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] Attached Figure 1 : HPLC chromatogram of reference substance solution of Example 1;
[0046] Attached Figure 2 : HPLC chromatogram of the test solution of Example 1;
[0047] Attached Figure 3 : HPLC chromatogram of the spiked test solution of Example 1;
[0048] Attached Figure 4 : HPLC chromatogram of the spiked test solution of Example 5;
[0049] Attached Figure 5 : High performance liquid chromatogram of Comparative Example 1. DETAILED DESCRIPTION
[0050] The following are some specific embodiments to illustrate the present invention. It is necessary to point out that the following specific embodiments are only used to further illustrate the present invention and do not limit the protection scope of the present invention. Some non-essential modifications and adjustments made by others based on the present invention still fall within the protection scope of the present invention.
[0051] In a specific implementation manner, the detection method is determined according to high performance liquid chromatography (General Rules 0512 of Part IV of the Chinese Pharmacopoeia 2020 Edition).
[0052] Example 1 Separation and detection method of the present invention
[0053] (1) Solution preparation (can be prepared with equal concentration or proportion)
[0054] Mobile phase A: Weigh 2.72 g of potassium dihydrogen phosphate, add 2000 ml of water to dissolve, then adjust the pH to 2.3 with phosphoric acid, mix well, and filter to obtain;
[0055] Mobile phase B: about 1000 ml of acetonitrile, ultrasonic for 20 minutes;
[0056] Needle washing solution: methanol;
[0057] Solvent: Take 500ml of water, 400ml of acetonitrile, 100ml of methanol, and 10ml of glacial acetic acid respectively, mix well, and obtain;
[0058] Reference substance stock solution: Take 10 mg of each impurity A, B, C, and D reference substance, accurately weigh, place in a 100 ml volumetric flask, add solvent to dissolve and dilute to the scale, shake well; accurately measure 5 ml, place in a 100 ml volumetric flask, dilute to the scale with solvent, shake well, and obtain;
[0059] Reference substance solution: accurately measure 2 ml of reference substance stock solution, place in a 20 ml volumetric flask, dilute to scale with solvent, shake well, and obtain (starting from weighing, prepare 2 portions in parallel);
[0060] Test solution: Take about 13 mg of the test sample (brepazole), accurately weigh it, put it in a 10 ml volumetric bottle, add an appropriate amount of solvent and sonicate to dissolve it, dilute it to the scale with solvent, shake well, and obtain (prepare 2 portions in parallel);
[0061] Spiked test solution: Take about 13 mg of the test sample (brepazole), accurately weigh it, put it in a 10 ml volumetric flask, add an appropriate amount of solvent and sonicate to dissolve it, then accurately add 1 ml of the reference stock solution, dilute to the scale with solvent, shake well, and obtain;
[0062] (2) Chromatographic conditions
[0063] Chromatographic column: InertSustain C18 (4.6*150mm, 3μm);
[0064] Ghost peak trapping column: Welch Ghost-Bustr Column 4.6*50mm;
[0065] Detection wavelength: 230 nm, injection volume: 10 μl, flow rate: 1.0 ml / min, column temperature: 40 °C, mobile phase A: 10 mmol / L potassium dihydrogen phosphate solution (pH 2.3), mobile phase B: acetonitrile, diluent: water-acetonitrile-methanol-glacial acetic acid (50:40:10:1);
[0066] Perform gradient elution according to Table 1:
[0067] Table 1
[0068] Time (min) Mobile phase A (%) Mobile phase B (%) 0 85 15 50 30 70 50.1 85 15 60 85 15
[0069] (3) Determined by HPLC (Chinese Pharmacopoeia 2020 Edition Part IV General Rules 0512), the calculation method was external standard method, the separation of each substance was good, the measured HPLC spectrum is shown in the attached Figure 1-3 .
[0070] (4) Precision
[0071] Accurately measure 10 μl of the control solution and inject it into the liquid chromatograph for detection. Inject the sample 6 times continuously. The injection precision results are shown in Table 2 and Table 3:
[0072] Table 2 Injection precision-retention time
[0073] name Impurity C(min) Impurity A(min) Impurity D(min) Impurity B(min) 1 25.965 35.484 44.757 46.938 2 25.963 35.471 44.745 46.928 3 25.951 35.441 44.727 46.912 4 25.945 35.431 44.725 46.909 5 25.960 35.466 44.750 46.940 6 25.968 35.466 44.748 46.937 RSD(%) 0.1 0.1 0.1 0.1
[0074] Table 3 Injection precision-peak area
[0075] name Impurity C Impurity A Impurity D Impurity B 1 28.877 32.066 39.686 33.539 2 29.068 32.236 39.861 33.676 3 28.897 32.151 39.774 33.674 4 28.951 32.186 39.796 33.645 5 28.984 32.175 39.809 33.574 6 28.956 32.253 39.670 33.576 RSD(%) 0.3 0.3 0.2 0.2
[0076] (5) Solution stability
[0077] When the reference solution was placed at room temperature for 77.5 h (about 3 days), the peak area was less than 10.0% compared with that at 0 h.
[0078] The test solution was placed at room temperature for 76.5h (about 3 days), and the content of impurity C was calculated by external standard method. The detected amount was basically consistent with that at 0h, meeting the requirements, and the other impurities were not detected.
[0079] This indicates that the reference solution is stable within 77.5 hours (about 3 days) at room temperature, and the test solution is stable within 76.5 hours (about 3 days) at room temperature.
[0080] Example 2 Limit of detection (LOD) and limit of quantification (LOQ) of the separation and detection method of the present invention
[0081] Solvent: water-acetonitrile-methanol-glacial acetic acid (50:40:10:1);
[0082] Impurity C stock solution: Take 10 mg of the impurity C reference substance, weigh accurately, place in a 100 ml volumetric flask, add an appropriate amount of solvent, dissolve by ultrasonication, dilute to the scale with solvent, and shake well (prepare impurity A, impurity B, impurity D reference substance stock solutions in the same way);
[0083] Reference substance stock solution: accurately measure 5 ml of each impurity stock solution, place it in the same 100 ml volumetric flask, dilute to the mark with solvent, shake well, and the solution is ready;
[0084] Reference substance solution: accurately measure 2 ml of reference substance stock solution, place in a 20 ml volumetric flask, dilute to scale with solvent, shake well, and obtain;
[0085] Limit of quantitation solution (LOQ): Accurately measure 1 ml of the reference solution, place it in a 25 ml volumetric flask, add solvent to dilute to the mark, and shake well;
[0086] Limit of detection solution (LOD): Accurately measure 5 ml of limit of quantitation solution, place in a 10 ml volumetric flask, add solvent to dilute to the scale, and shake well;
[0087] Take blank solution, quantitative limit solution and detection limit solution for injection respectively and record the chromatogram. The results are shown in Table 4-7:
[0088] Table 4 Quantitation limit test (S / N)
[0089] name LOQ-1 LOQ-2 LOQ-3 LOQ-4 LOQ-5 LOQ-6 Impurity C 57 65 73 56 58 52 Impurity A 62 74 79 62 64 58 Impurity D 48 57 63 48 51 45 Impurity B 52 62 71 53 53 49
[0090] Table 5 Quantitation limit test (peak area)
[0091] name LOQ-1 LOQ-2 LOQ-3 LOQ-4 LOQ-5 LOQ-6 RSD(%) Impurity C 1.183 1.132 1.170 1.085 1.141 1.088 3.6 Impurity A 1.184 1.223 1.222 1.253 1.241 1.195 2.2 Impurity D 1.438 1.531 1.498 1.534 1.514 1.478 2.5 Impurity B 1.190 1.256 1.319 1.316 1.202 1.195 4.9
[0092] Table 6 Quantitation limit test
[0093]
[0094] Table 7 Detection limit test
[0095]
[0096] Conclusion: The S / N of the quantitative limit solution of each impurity is greater than 10, the concentration is less than 5.0% of the limit concentration, and the RSD value of the peak area of 6 consecutive injections is less than 15.0%, indicating that this method meets the quantitative detection requirements; the S / N of the detection limit solution of each impurity is greater than 3, and the concentration is less than 3.0% of the limit concentration, which can meet the detection requirements.
[0097] Example 4 Linearity and range of the separation and detection method of the present invention
[0098] Solvent: water-acetonitrile-methanol-glacial acetic acid (50:40:10:1);
[0099] Reference substance stock solution: prepared as in Example 2;
[0100] Accurately measure 4 ml → 20 ml of the reference substance stock solution (equivalent to 200% of the limit concentration);
[0101] Accurately measure 3 ml → 20 ml of the reference stock solution (equivalent to 150% of the limit concentration);
[0102] Accurately measure 2 ml → 20 ml of the reference substance stock solution (equivalent to the limit concentration of 100%);
[0103] Accurately measure 1 ml → 20 ml of reference stock solution (equivalent to 50% limit concentration)
[0104] The chromatographic conditions were the same as those in Example 1. A blank solution and the above solution were injected respectively, and the chromatograms were recorded.
[0105] The results show that: when the concentration of impurity C is in the range of 0.0207 to 1.0340 μg / ml, which is equivalent to 4.2% to 212.1% of the limit concentration, the linear equation is y=56.3840x-0.0404, and the correlation coefficient r is 1.0000, which is greater than 0.9900; the ratio of the Y-axis intercept to the 100% limit concentration peak area is 0.1%, which is less than 10.0%, and the concentration and peak area show a good linear relationship.
[0106] The concentration of impurity A is in the range of 0.0208 to 1.0419 μg / ml, which is equivalent to 4.3% to 213.7% of the limit concentration. The linear equation is y=61.8400x-0.0777, and the correlation coefficient r is 1.0000. The ratio of the Y-axis intercept to the 100% limit concentration peak area is 0.2%, which is less than 10.0%. The concentration and the peak area show a good linear relationship.
[0107] The concentration of impurity D is in the range of 0.0207 to 1.0339 μg / ml, which is equivalent to 4.2% to 212.1% of the limit concentration. The linear equation is y=75.9674x-0.0710, and the correlation coefficient r is 1.0000, which is greater than 0.9900. The ratio of the Y-axis intercept to the 100% limit concentration peak area is 0.2%, which is less than 10.0%, and the concentration and the peak area show a good linear relationship.
[0108] The concentration of impurity B is in the range of 0.0200 to 1.0005 μg / ml, which is equivalent to 4.1% to 205.2% of the limit concentration. The linear equation is y=67.5724x-0.1844, and the correlation coefficient r is 1.0000, which is greater than 0.9900. The ratio of the Y-axis intercept to the 100% limit concentration peak area is 0.6%, which is less than 10.0%, and the concentration and the peak area show a good linear relationship.
[0109] Example 5 Separation test of the present invention
[0110] The chromatographic conditions were the same as in Example 1;
[0111] Take the related impurities of breprazol (7-hydroxy-2-quinolone, 1-(benzo[b]thiophen-4-yl)piperazine, 7,7'-(butane-1,4-diylbis(oxy))bis(quinolin-2(1H)-one), 4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazine-1-oxide, 4-(benzo[b]thiophen-4-yl)-1,1-bis(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazine-1-ammonium chloride, 7-(4-(4-(benzothiophen-4-yl)piperazine-1-yl)butyloxy)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazine-1-ammonium chloride 1,2-dihydroquinolin-7-yl)oxy)butyl)quinolin-2(1H)-one, 7-(4-((7-(4-(4-(benzo[b]thien-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl)oxy)butoxy)quinolin-2(1H)-one, 2,7-bis(4-(4-(benzo[b]thien-4-yl)piperazin-1-yl)butoxy)quinoline, 7-(4-(4-(benzothien-4-yl)piperazin-1-yl)butoxy)-1-(4-(4-(benzothien-4-yl)piperazin-1-yl)butyl)quinolin-2(1H)-one), each in appropriate amount, add diluent to dissolve and dilute to prepare a mixed solution containing 2μg of each impurity per 1ml. Inject the separation solution into the liquid chromatograph, and the test results are shown in the attached Figure 4 .
[0112] The results showed that the related impurities of brepazole had no interference at the peak positions of impurity A, impurity B, impurity C and impurity D.
[0113] Comparative Example 1
[0114] (1) Chromatographic conditions:
[0115] Chromatographic column: InertSustain C18 (4.6×150mm, 3μm);
[0116] Ghost peak trapping column: Welch Ghost-Bustr Column 4.6×50mm;
[0117] Detection wavelength: 254nm, injection volume: 10μl, flow rate: 1.0ml / min, column temperature: 35℃, mobile phase A: 0.1% trifluoroacetic acid solution, mobile phase B: acetonitrile-methanol-trifluoroacetic acid (50:40:10:1), diluent: water-acetonitrile-methanol-glacial acetic acid (50:40:10:1); perform gradient elution according to the following table:
[0118] Time (min) Mobile phase A (%) Mobile phase B (%) 0 70 30 50 35 65 50.1 70 30 60 70 30
[0119] Preparation of separation solution: take brepazine and brepazine related impurities (7-hydroxy-2-quinolone, 1-(benzo[b]thiophen-4-yl)piperazine, 7,7'-(butane-1,4-diylbis(oxy))bis(quinolin-2(1H)-one), 4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazine-1-oxide, impurity C, 4-(benzo[b]thiophen-4-yl)-1,1-bis(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazine-1-ammonium chloride, 7-(4-(4-(benzothiophen-4-yl)piperazine-1-yl)butyloxy)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazine-1-ammonium chloride, An appropriate amount of 1,2-dihydroquinolin-7-yl)oxy)butyl)quinolin-2(1H)-one, 7-(4-((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl)oxy)butoxy)quinolin-2(1H)-one, 2,7-bis(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinoline, impurity D, 7-(4-(4-(benzothiophen-4-yl)piperazin-1-yl)butoxy)-1-(4-(4-(benzothiophen-4-yl)piperazin-1-yl)butyl)quinolin-2(1H)-one), a diluent is added to dissolve and dilute to prepare a mixed solution containing 1 mg of breprazol and 1 μg of each impurity per 1 ml.
[0120] Inject the separation solution into the liquid chromatograph and see the test results in the attached Figure 5 From the attached Figure 5 It can be seen that impurity C and 4-(benzo[b]thiophene-4-yl)-1,1-bis(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazine-1-ammonium chloride did not achieve baseline separation (retention times were 21.125 min and 21.387 min, respectively).
[0121] The above description of the specific embodiments of the present invention does not limit the present invention. Those skilled in the art may make various changes or modifications based on the present invention. As long as they do not depart from the spirit of the present invention, they should all fall within the scope of protection of the claims of the present invention.
Claims
1. A method for separating and detecting genotoxic impurities in brepazole by high performance liquid chromatography, wherein the chromatographic column is a C18 column, the mobile phase A is a phosphate aqueous solution, the mobile phase B is acetonitrile, and the gradient elution is performed, and the related substance is selected from any one of impurity A, impurity B, impurity C, and impurity D or a combination thereof.
2. The method according to claim 1, wherein the phosphate is selected from any one of potassium dihydrogen phosphate, sodium dihydrogen phosphate, dipotassium hydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, and potassium phosphate, or a combination thereof.
3. The method according to claim 1, wherein the concentration of the phosphate aqueous solution in the mobile phase A is 5 to 20 mmol / L, preferably 8 to 15 mmol / L.
4. The method according to claim 1, wherein an acid is added to the mobile phase A, and the acid is selected from any one of phosphoric acid, formic acid, and acetic acid, or a combination thereof.
5. The method according to claim 1, wherein the pH value of mobile phase A is 2.2 to 3.0, preferably 2.2 to 2.
5.
6. According to the method of claim 1, a ghost peak capture column is installed between the pump and the injector of the high performance liquid chromatograph.
7. The method according to claim 1, wherein at 0 to 50 min, the volume ratio of mobile phase A to mobile phase B is 90:10 to 30:
70.
8. The method according to claim 1, wherein any one of the test substance, the test sample, and the reference substance is dissolved or diluted with a dissolving solvent, the dissolving solvent is a combination of water, acetonitrile, methanol, and glacial acetic acid, and the volume ratio of water, acetonitrile, methanol, and glacial acetic acid in the dissolving solvent is 50:40:10:
1.
9. Use of any one of brepirazole and / or its genotoxic impurities separated and purified by the method of any one of claims 1 to 8 as a standard or reference substance.
10. Use of the method according to any one of claims 1 to 22 in the quality control of brepirazoline raw materials and / or preparations thereof.
